Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:1163-1169
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mathew, V.
Right arrow Articles by Holmes, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathew, V.
Right arrow Articles by Holmes, D. R., Jr.

The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions

Verghese Mathew, MDa, Diane E. Grill, MSa, Christopher G. Scott, BSa, J. Aaron Grantham, MDa, Henry H. Ting, MDa, Kirk N. Garratt, MD, FACCa and David R. Holmes, Jr., MD, FACCa

a Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA



View larger version (11K):

[in a new window]
  		Figure 1 Adjusted survival estimates of freedom from death/MI/repeat revascularization from the time of procedure onwards with abciximab versus without abciximab. MI = myocardial infarction.

 


View larger version (11K):

[in a new window]
  		Figure 2 Adjusted survival estimates of freedom from death/MI/repeat revascularization from the time of procedure onwards with pretreatment with abciximab versus without abciximab. MI = myocardial infarction.

 
 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement